Ratios

		vs industry	vs history
P/E(ttm)	48.20	HAE's P/E(ttm) is ranked lower than 51% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 25.40 vs. HAE: 48.20 )	HAE' s 10-Year P/E(ttm) Range Min: 15.62   Max: 1543.8 Current: 48.2 15.62 1543.8
P/B	2.90	HAE's P/B is ranked lower than 57% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 2.41 vs. HAE: 2.90 )	HAE' s 10-Year P/B Range Min: 1.81   Max: 4.59 Current: 2.9 1.81 4.59
P/S	2.60	HAE's P/S is ranked lower than 53% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 2.40 vs. HAE: 2.60 )	HAE' s 10-Year P/S Range Min: 1.24   Max: 3.59 Current: 2.6 1.24 3.59
PFCF	82.10	HAE's PFCF is ranked lower than 76% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 23.35 vs. HAE: 82.10 )	HAE' s 10-Year PFCF Range Min: 10.33   Max: 187.55 Current: 82.1 10.33 187.55
EV-to-EBIT	40	HAE's EV-to-EBIT is ranked lower than 55% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 16.12 vs. HAE: 40 )	HAE' s 10-Year EV-to-EBIT Range Min: 9.9   Max: 65.8 Current: 40 9.9 65.8
PEG	4.7	HAE's PEG is ranked higher than 85% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 1.70 vs. HAE: 4.7 )	HAE' s 10-Year PEG Range Min: 1.27   Max: 11.29 Current: 4.7 1.27 11.29
Shiller P/E	33.7	HAE's Shiller P/E is ranked higher than 69% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 23.85 vs. HAE: 33.7 )	HAE' s 10-Year Shiller P/E Range Min: 21.83   Max: 44.04 Current: 33.7 21.83 44.04

Valuation & Return

		vs industry	vs history
Price/Net Cash	41.9	HAE's Price/Net Cash is ranked lower than 68% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 11.40 vs. HAE: 41.9 )	HAE' s 10-Year Price/Net Cash Range Min: 9.5   Max: 85.1 Current: 41.9 9.5 85.1
Price/Net Current Asset Value	13.2	HAE's Price/Net Current Asset Value is ranked higher than 60% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 12.40 vs. HAE: 13.2 )	HAE' s 10-Year Price/Net Current Asset Value Range Min: 6.1   Max: 14.7 Current: 13.2 6.1 14.7
Price/Tangible Book	4.1	HAE's Price/Tangible Book is ranked higher than 91% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 4.80 vs. HAE: 4.1 )	HAE' s 10-Year Price/Tangible Book Range Min: 2.9   Max: 4.6 Current: 4.1 2.9 4.6
Price/DCF (Projected)	1.7	HAE's Price/DCF (Projected) is ranked lower than 76% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 1.20 vs. HAE: 1.7 )	HAE' s 10-Year Price/DCF (Projected) Range Min: 1.3   Max: 1.9 Current: 1.7 1.3 1.9
Price/Median PS Value	1	HAE's Price/Median PS Value is ranked lower than 73% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 0.90 vs. HAE: 1 )	HAE' s 10-Year Price/Median PS Value Range Min: 0.7   Max: 1.3 Current: 1 0.7 1.3
Price/Graham Number	2.4	HAE's Price/Graham Number is ranked higher than 99% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 2.30 vs. HAE: 2.4 )	HAE' s 10-Year Price/Graham Number Range Min: 1.6   Max: 5 Current: 2.4 1.6 5
Earnings Yield (Greenblatt)	2.50	HAE's Earnings Yield (Greenblatt) is ranked higher than 64% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 5.70 vs. HAE: 2.50 )	HAE' s 10-Year Earnings Yield (Greenblatt) Range Min: 1.5   Max: 10.1 Current: 2.5 1.5 10.1
Forward Rate of Return (Yacktman)	6.88	HAE's Forward Rate of Return (Yacktman) is ranked higher than 75% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 8.11 vs. HAE: 6.88 )	HAE' s 10-Year Forward Rate of Return (Yacktman) Range Min: 7.2   Max: 17.4 Current: 6.88 7.2 17.4

Business Description

Haemonetics Corporation was founded in 1971 and incorporated in Massachusetts in 1985. The company is a healthcare company which provides blood management solutions to its customers. Its portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain, helping improve clinical outcomes and reduce costs for blood and plasma collectors, hospitals, and patients around the world. Its market segment includes Plasma: Its portfolio of products and services is designed to support multiple facets of plasma collector operations. It offers 'one stop shopping' to its plasma collection customers, enabling them to source from it the full range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and consumables, plasma collection containers, and intravenous solutions. Its plasma disposables product line represented 35.5%, 33.6%, and 36.0% of its total revenue in fiscal 2012, 2011 and 2010, respectively. Blood center: The Company offers automated blood component collection systems to blood collection centers to collect blood products. It markets the MCS (Multicomponent Collection System) brand apheresis equipment which is designed to collect specific blood components and return the unwanted components to the donor. The MCS automated platelet system collects one or more therapeutic 'doses' of platelets during a single donation by a volunteer blood donor. Its blood center disposables product line represented 29.7%, 30.0%, and 30.8% of its total revenue in fiscal 2012, 2011 and 2010, respectively. Hospital: The Company offers a range of blood management solutions that improve a hospital's systems for acquiring blood, storing it in the hospital, and dispensing it correctly. Its TEG Thromobelastograph Hemostasis Analyzer system is a blood diagnostic instrument that measures a patient's hemostasis or the ability to form and maintain blood clots. Its Cell Saver system is a surgical blood salvage system targeted to procedures that involve rapid, high-volume blood loss, such as cardiovascular surgeries. It has become the standard of care for high blood-loss surgeries. In fiscal 2012, the company launched its newest device, the Cell Saver Elite system, which is its advanced autotransfusion option to minimize allogeneic blood use for surgeries. Software Solutions: To complement its device and disposable products, it has a suite of integrated software solutions that track and monitor blood units along all points in the supply chain, including blood drive planning, donor recruitment and retention, blood processing, blood distribution, and transfusion management. For its plasma customers, the company also provides information technology platforms for managing administrative functions and distribution at plasma fractionation facilities. While each Haemonetics information technology platform can be used as a 'stand-alon
Company Website
SEC Reports

Industry:	Medical Instruments & Supplies
Compare:	WST, BAX, COV, TMO, COO

» More Articles for HAE

Headlines

Articles On GuruFocus.com

Allscripts-Misys Reports 5 Insider Buys the Day Before Barclays Conference Mar 13 2013

Weekly Guru Bargains Highlights: HAE, DLTR, QCOR, MTX, AMD Jan 21 2013

Weekly Guru Bargains Highlights: CIG, ARO, NKE, DLTR, HAE Jan 13 2013

Weekly Guru Bargains Highlights: FTNT, VVUS, HAE, PC, TIBX Dec 09 2012

Haemonetics Corp. Reports Operating Results (10-Q) Feb 08 2011

Haemonetics Corp. (HAE) CFO & Vice President of Christopher J Lindop sells 17,832 Shares Dec 14 2010

Haemonetics Corp. Reports Operating Results (10-Q) Nov 10 2010

Haemonetics Corp. Reports Operating Results (10-Q) Aug 11 2010

Haemonetics Corp. (HAE) Chairman of the Board Brad Nutter sells 26,872 Shares Mar 26 2010

Haemonetics Corp. (HAE) Chairman of the Board Brad Nutter sells 173,128 Shares Mar 24 2010

Personalized Checklist